There is growing interest in the field of in vitro 3D models for understanding potential drug-induced toxicity. Models for cardiotoxicity are some of the most sophisticated, with iPSC-derived cardiomyocytes being introduced allowing the tissues to beat in a manner similar to a human heart. Incorporating different cell types into the 3D models also enables multicellular models to be developed to mimic the structural components of the human heart within the body.
Cyprotex has specialist expertise in this field and in July launched a new 3D hypertrophy and structural cardiotoxicity model. The model allows long term repeat dosing over 14 days, and combines a continuous monitoring of hypertrophy, and a terminal assessment of structural cardiotoxicity.